Bridgeway Capital Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Bridgeway Capital Management’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-174,800	Closed	-$1.59M	–	1479
2018 Q1	$1.59M	Sell	174,800 -120,000	-41%	-$662K	0.02%	670
2017 Q4	$1.26M	Sell	294,800 -40,000	-12%	-$191K	0.01%	753
2017 Q3	$472K	Hold	334,800	–	–	0.01%	1111
2017 Q2	$502K	Buy	334,800 +139,000	+71%	+$298K	0.01%	1089
2017 Q1	$503K	Hold	195,800	–	–	0.01%	1073
2016 Q4	$499K	Hold	195,800	–	–	0.01%	1093
2016 Q3	$605K	Hold	195,800	–	–	0.01%	1005
2016 Q2	$629K	Buy	195,800 +20,900	+12%	+$76.6K	0.01%	950
2016 Q1	$542K	Hold	174,900	–	–	0.01%	1013
2015 Q4	$701K	Hold	174,900	–	–	0.01%	913
2015 Q3	$801K	Hold	174,900	–	–	0.02%	829
2015 Q2	$908K	Buy	174,900 +50,000	+40%	+$300K	0.02%	826
2015 Q1	$782K	Hold	124,900	–	–	0.02%	897
2014 Q4	$786K	Buy	+124,900	New	+$761K	0.02%	867

Other funds holding ECYT

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bridgeway Capital Management's ECYT Position: Q2 2018 in Review

Bridgeway Capital Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q2 2018, closing a stake of 174,800 shares — an estimated $1.59M sold.

Bridgeway Capital Management first reported a position in ECYT in Q4 2014 and held it in 14 quarters. The position peaked at $1.59M in Q1 2018. 114 funds tracked by Wall St. Rank hold ECYT as of Q2 2018.

Bridgeway Capital Management reported no remaining Endocyte, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
Bridgeway Capital Management sold 174,800 Endocyte, Inc. Common Stock shares in Q2 2018, an estimated $1.59M.
Bridgeway Capital Management first reported a position in Endocyte, Inc. Common Stock in Q4 2014 and held it in 14 quarters.
Bridgeway Capital Management's Endocyte, Inc. Common Stock position peaked at $1.59M in Q1 2018.
114 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q2 2018.

Based on Bridgeway Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.